| The ectonucleotidase CD39 identifies tumor-reactive CD8+ T cells predictive of immune checkpoint blockade efficacy in human lung cancer A Chow, FZ Uddin, M Liu, A Dobrin, BY Nabet, L Mangarin, Y Lavin, ... Immunity 56 (1), 93-106. e6, 2023 | 59 | 2023 |
| Targeting E-selectin to tackle cancer using uproleselan B Muz, A Abdelghafer, M Markovic, J Yavner, A Melam, NN Salama, ... Cancers 13 (2), 335, 2021 | 48 | 2021 |
| Bispecific T cell engagers for the treatment of multiple myeloma: achievements and challenges K Alhallak, J Sun, A Jeske, C Park, J Yavner, H Bash, B Lubben, ... Cancers 13 (12), 2853, 2021 | 14 | 2021 |
| Nanoparticle T cell engagers for the treatment of acute myeloid leukemia K Alhallak, J Sun, B Muz, A Jeske, J Yavner, H Bash, C Park, B Lubben, ... Oncotarget 12 (19), 1878, 2021 | 10 | 2021 |
| CD39 identifies tumor-reactive CD8 T cells in patients with lung cancer A Chow, FZ Uddin, L Mangarin, H Rizvi, A Dobrin, S Tischfield, ... | 2 | 2022 |
| Clinical and molecular correlates of CD39+ CD8 T cells in patients with lung cancer A Chow, FZ Uddin, L Mangarin, H Rizvi, A Dobrin, S Tischfield, ... bioRxiv, 2022.01. 24.477554, 2022 | | 2022 |
| Targeting E-selectin to Tackle Cancer Using Uproleselan. Cancers 2021, 13, 335 B Muz, A Abdelghafer, M Markovic, J Yavner, A Melam, NN Salama, ... s Note: MDPI stays neutral with regard to jurisdictional claims in published …, 2021 | | 2021 |
| Bispecific T Cell Engagers for the Treatment of Multiple Myeloma: Achievements and Challenges. Cancers 2021, 13, 2853 K Alhallak, J Sun, A Jeske, C Park, J Yavner, H Bash, B Lubben, ... s Note: MDPI stays neutral with regard to jurisdictional claims in published …, 2021 | | 2021 |
